Redefining the delivery of biologics to improve patient lives." title="" class="btn" data-container="body" data-html="true" data-id="4001" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="Elektrofi"> 152 7,977
Activities
Technologies
Entity types
Location
25 Drydock Ave # 2, Boston, MA 02210, USA
Boston
United States of America
Employees
Scale: 51-200
Estimated: 96
Engaged catalyst
3Added in Motherbase
6 years, 10 months agoFormulating the Future of BiologicsTM
Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally.
Formulating the Future of BiologicsTM. www.Elektrofi.com
Catalyst | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 31 Oct 2024 | | |
![]() NYSE Finance, Financial Services | NYSE Finance, Financial Services | Other 31 Oct 2024 | | |
![]() Takeda Pharmaceutical, Pharmaceutical Manufacturing | Takeda Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 30 Sep 2020 | |